Cargando…
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Although Akt is known as a survival kinase, inhibitors of the phosphatidylinositol 3-kinase (PI3K)–Akt pathway do not always induce substantial apoptosis. We show that silencing Akt1 alone, or any combination of Akt isoforms, can suppress the growth of tumors established from phosphatase and tensin...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2557046/ https://www.ncbi.nlm.nih.gov/pubmed/18838554 http://dx.doi.org/10.1083/jcb.200801099 |
_version_ | 1782159625901047808 |
---|---|
author | Degtyarev, Michael De Mazière, Ann Orr, Christine Lin, Jie Lee, Brian B. Tien, Janet Y. Prior, Wei W. van Dijk, Suzanne Wu, Hong Gray, Daniel C. Davis, David P. Stern, Howard M. Murray, Lesley J. Hoeflich, Klaus P. Klumperman, Judith Friedman, Lori S. Lin, Kui |
author_facet | Degtyarev, Michael De Mazière, Ann Orr, Christine Lin, Jie Lee, Brian B. Tien, Janet Y. Prior, Wei W. van Dijk, Suzanne Wu, Hong Gray, Daniel C. Davis, David P. Stern, Howard M. Murray, Lesley J. Hoeflich, Klaus P. Klumperman, Judith Friedman, Lori S. Lin, Kui |
author_sort | Degtyarev, Michael |
collection | PubMed |
description | Although Akt is known as a survival kinase, inhibitors of the phosphatidylinositol 3-kinase (PI3K)–Akt pathway do not always induce substantial apoptosis. We show that silencing Akt1 alone, or any combination of Akt isoforms, can suppress the growth of tumors established from phosphatase and tensin homologue–null human cancer cells. Although these findings indicate that Akt is essential for tumor maintenance, most tumors eventually rebound. Akt knockdown or inactivation with small molecule inhibitors did not induce significant apoptosis but rather markedly increased autophagy. Further treatment with the lysosomotropic agent chloroquine caused accumulation of abnormal autophagolysosomes and reactive oxygen species, leading to accelerated cell death in vitro and complete tumor remission in vivo. Cell death was also promoted when Akt inhibition was combined with the vacuolar H(+)–adenosine triphosphatase inhibitor bafilomycin A1 or with cathepsin inhibition. These results suggest that blocking lysosomal degradation can be detrimental to cancer cell survival when autophagy is activated, providing rationale for a new therapeutic approach to enhancing the anticancer efficacy of PI3K–Akt pathway inhibition. |
format | Text |
id | pubmed-2557046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-25570462009-04-06 Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents Degtyarev, Michael De Mazière, Ann Orr, Christine Lin, Jie Lee, Brian B. Tien, Janet Y. Prior, Wei W. van Dijk, Suzanne Wu, Hong Gray, Daniel C. Davis, David P. Stern, Howard M. Murray, Lesley J. Hoeflich, Klaus P. Klumperman, Judith Friedman, Lori S. Lin, Kui J Cell Biol Research Articles Although Akt is known as a survival kinase, inhibitors of the phosphatidylinositol 3-kinase (PI3K)–Akt pathway do not always induce substantial apoptosis. We show that silencing Akt1 alone, or any combination of Akt isoforms, can suppress the growth of tumors established from phosphatase and tensin homologue–null human cancer cells. Although these findings indicate that Akt is essential for tumor maintenance, most tumors eventually rebound. Akt knockdown or inactivation with small molecule inhibitors did not induce significant apoptosis but rather markedly increased autophagy. Further treatment with the lysosomotropic agent chloroquine caused accumulation of abnormal autophagolysosomes and reactive oxygen species, leading to accelerated cell death in vitro and complete tumor remission in vivo. Cell death was also promoted when Akt inhibition was combined with the vacuolar H(+)–adenosine triphosphatase inhibitor bafilomycin A1 or with cathepsin inhibition. These results suggest that blocking lysosomal degradation can be detrimental to cancer cell survival when autophagy is activated, providing rationale for a new therapeutic approach to enhancing the anticancer efficacy of PI3K–Akt pathway inhibition. The Rockefeller University Press 2008-10-06 /pmc/articles/PMC2557046/ /pubmed/18838554 http://dx.doi.org/10.1083/jcb.200801099 Text en © 2008 Degtyarev et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Research Articles Degtyarev, Michael De Mazière, Ann Orr, Christine Lin, Jie Lee, Brian B. Tien, Janet Y. Prior, Wei W. van Dijk, Suzanne Wu, Hong Gray, Daniel C. Davis, David P. Stern, Howard M. Murray, Lesley J. Hoeflich, Klaus P. Klumperman, Judith Friedman, Lori S. Lin, Kui Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents |
title | Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents |
title_full | Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents |
title_fullStr | Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents |
title_full_unstemmed | Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents |
title_short | Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents |
title_sort | akt inhibition promotes autophagy and sensitizes pten-null tumors to lysosomotropic agents |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2557046/ https://www.ncbi.nlm.nih.gov/pubmed/18838554 http://dx.doi.org/10.1083/jcb.200801099 |
work_keys_str_mv | AT degtyarevmichael aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT demaziereann aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT orrchristine aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT linjie aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT leebrianb aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT tienjanety aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT priorweiw aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT vandijksuzanne aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT wuhong aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT graydanielc aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT davisdavidp aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT sternhowardm aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT murraylesleyj aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT hoeflichklausp aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT klumpermanjudith aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT friedmanloris aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents AT linkui aktinhibitionpromotesautophagyandsensitizesptennulltumorstolysosomotropicagents |